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ABSTRACT
Introduction : A retrospective cohort study was conducted among ESRD who received dialysis 
treatment (Haemodialysis and CAPD) in all government hospitals in the State of 
Pahang from 1st January 2000 to 31st December 2004.
Objective      : The aim of the study was to identify factors affecting the survival of patients 
undergoing dialysis in the state of Pahang.
Methods       : Survival time was measured from the date of dialysis until the subjects died, lost to 
follow up or until the end of the study period at 31st December 2004. 
Results          : Diabetes mellitus was the major cause for ESRD (33%) out of 132 subjects eligible for 
the study. Seven (7.1%) and five (15.2%) deaths occurred among haemodialysis and 
CAPD patients respectively, but statistically of no difference between the two 
treatments (log-rank, p=0.093). Factors influencing the survival of haemodialysis
patients were diabetes mellitus (p=0.014), albumin (p=0.0005), creatinine (p=0.020) 
and hemoglobin level (p=0.002), while age of treatment and diabetes mellitus affecting 
the survival of CAPD patient. Cox Proportional Hazard Regression showed that 
haemodialysis subjects with low albumin (HR 0.669 df 95% 0.513 - 0.873) and 
hemoglobin (HR 0.403 df 95% 0.225 - 0.720) level had lower survival rate but none for 
CAPD. 
Conclusion  : Good nutritional status, higher hemoglobin level and prevention of diabetes mellitus are 
important for the survival of haemodialysis patient. 
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INTRODUCTION
Kidney is an important organ in humans. Any 
disease that can affect its function can cause 
various problems to our body such as 
accumulation of body waste, acid-base 
imbalance and reduction of hormone production. 
End stage renal disease failure (ESRD) is a 
spectrum of chronic renal failure where there is 
irreversible function loss which leads to a clinical 
syndrome known as uraemia. 
The incidence and prevalence of ESRD 
is increasing every year worldwide and almost all 
of them are related to the increasing incidence of 
diabetes mellitus1. In United State of America 
(USA) the number of patients is expected to 
increase to 600,000 in 2008 from 256,000 in 
19982. The same scenario also happened in 
Malaysia where the prevalence increased from 
59 in 1980 to 8954 in 20023. There are two kinds 
of treatment commonly delivered to these 
patients especially when the conservative 
treatment fails to slow down the progression of 
the disease: The Renal Replacement Therapy 
(RRT) which includes haemodialysis and 
continuous ambulatory peritoneal dialysis 
(CAPD), and Renal Transplantation4,5. In 
Malaysia, haemodialysis treatment is the most 
commonly received by ESRD patient (80 to 
90%) as compared to CAPD3.
The dialysis treatment has benefitted 
most of the ESRD patients by reducing their 
morbidity and mortality. In Malaysia the number 
of patients receiving dialysis treatment has 
increased from 59 in 1980 to 10,000 in 2003 but 
the mortality rate has been stable at 10% per year 
since 1980 till 2003 although there is an 
advancement of dialysis technology and increase 
of dialysis facilities in the country3. 
A lot of studies has been done to identify the 
factors that can influence the patients’ mortality. 
One study found that CAPD patients have 19% 
higher mortality rate (RR 1.19; p< 0.001) 
compared to haemodialysis, but another revealed 
that CAPD patients have a 27% lower mortality 
(RR 0.73; 95% CI: 0.68-0.78)6,7. Yet another 
study has found a better survival rate among 
CAPD patients for the first 2 years of treatment 
(RR 0.65; 0.59-0.72, p<0.001)8. The increasing 
age, alcoholism and the present diabetes mellitus 
and cardiovascular disease (CVD) have reduced 
the survival rate, but it is not affected by 
hypertension or sex. It was shown that the 
survival was reduced by increasing of age, 
smoking and the presence of diabetes mellitus, 
ischemic heart disease, arteriosclerosis and 
cancer9.
Studies found that malnutrition factors 
such as low albumin, urea and creatinine level 
reduces the patient’s survival rate10,11. 
Surprisingly higher cholesterol level will benefit 
the patients survival especially for those with 
systemic inflammation12,10,11. Meanwhile body 
mass index of more than 30kg/m2 increased the 
survival rate of haemodialysis patients13,14,15,16. 
Other factor identified influences the survival 
rate was the adequacy of treatment, measured by 
Kt/V (K= dialysis clearance, t = duration of 
treatment session, V = volume of body fluid), 
whereby the higher Kt/V can reduce the 
mortality risk17. The Kt/V value of 1.2 is 
considered adequate for the dialysis of patients 
18,19.
It is clear that different studies will give 
different findings regarding factors affecting the 
survival of patients especially in the early phase 
of treatment. It could be happens because of the 
different methodology or the cohort of patients 
being used and also biases that can exist in the 
study. 
GENERAL OBJECTIVE
To measure the survivorship of ESRD patient 
who received dialysis treatment at the 
government hospital in the state of Pahang and 
the influencing factors. 
SPECIFIC OBJECTIVES
To identify sociodemographic characteristics 
(age, sex, ethnicity, educational level, marital 
status, income and method of payment) of which 
affected the survival of the patients and also 
according to the method of dialysis.
2. To compare the survivorship between patients 
who received haemodialysis and CAPD for the 5 
years period of treatment (5-year survival), and 
also according to the sociodemographic factors 
(age of first treatment, sex, ethnicity, educational 
level, marital status, income and method of 
payment); co-morbidities like diabetes mellitus, 
hypertension and cardiovascular disease; 
nutritional parameters like body mass index 
(BMI), albumin, cholesterol, triglyceride, urea 
and haemoglobin level; and the adequacy of 
dialysis by Kt/V value 
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METHODOLOGY
This was a survival analysis study of 
retrospective cohort design, using clinic-held 
records of ESRD patients, who were receiving 
dialysis treatment (Haemodialysis and CAPD) in 
all government hospitals in the State of Pahang 
from 1st January 2000 to 31st December 2004.
The subjects were selected through universal 
sampling technique and the required sample size 
was counted by using “Power and Sample Size 
Calculation’ version 2.1.31 software. A total of 
114 subjects were needed in this study. The 
required data were extracted from the record of 
dialysis clinic and were entered into the 
statistical software. Survival time was measured 
from the date of initial dialysis until the subjects 
died, lost of follow-up or achieving the end of 
the study period at 31st December 2004.
Inception cohort
The patients recruited to the study were 
drawn from all patients referred to in the 
government dialysis centres in Pahang between 1 
Jan 2000 and 31 Dec 2004. They were further 
followed up until 30 June 2005 to ascertain their 
survival outcome. Patients were included in this 
analysis if their disease onset occurred before 1 
January 2000 and the first dialysis treatment was 
in or after 1 January 2000. The disease onset 
defined as those having the symptoms of and 
diagnosed as ESRD by the nephrologist. Patients 
who were first referred and received dialysis 
treatment before 1 January 2000, although had 
had a disease onset prior to this date, were 
excluded. All the patients included satisfied the 
criteria for ESRD. Detailed clinical, laboratory 
and other relevant information was abstracted 
from the patients' records, much of which is held 
on their respective records. The patients were 
subdivided into those undergoing haemodialysis 
and peritoneal dialysis.
Censored cases
The patients who were still alive at the 
end of the study period (31st December 2004) or 
to have unknown outcome were classified as 
censored cases. 
Statistical Analysis
Statistical analysis was conducted using 
SPSS version 11.5. The basic characteristics of 
the subjects were tested χ2-test for qualitative 
data and t-test for normally distributed 
quantitative data, whereas for non-normally 
distributed quantitative data were analysed by 
Mann-Whitney U test. Survival distribution of 
the patient was calculated by Kaplan-Meier and 
the difference of survival rates between the 
independent factors were tested by log-rank test. 
Multivariate survival analysis was then carried 
out using Cox Proportional Hazard Regression. 
Level of significance was determined by using 
the 95% confidence interval and p-value <0.05 
(two-tailed). 
RESULT
A total of 132 (67%) subjects were 
eligible out of 197 registered and receiving 
dialysis treatments from 1st January until 31st
December 2004. The age factor was normally 
distributed with the min and median at 50 and 51 
years respectively. There were more male 
subjects (59.8%), of Malay ethnicity (65.7%), 
married (82.6%), have secondary or higher 
educational level (59.1%), income of less than 
RM1000 per month (61.4%) and have free or 
fully subsidised treatment from the government 
(TABLE 1). diabetes mellitus has been identified 
as major cause of ESRD (33%) but for the 
majority of the cases, the cause were unknown 
(40.2%) (TABLE 2).
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Table 1  Sociodemographic Distribution Of The Subjects
Factors Characteristics No of subject (n=132) %
Sex Male 79 59.8
Female 53 40.2
Age of treatment < 25 year old 7 5.3
25 – 34 14 10.6
35 – 44 16 12.1
45 – 54 47 35.6
55 – 64 30 22.7
65 – 74 15 11.4
> 74 year old 3 2.3
Ethnic Malay 87 65.9
Non- Malay 45 34.1
Marital status Married 109 82.6
Single 23 17.4
Educational level Primary school and less 54 40.9
Secondary school and upper 78 59.1
Income < RM1000 81 61.4
> RM1000 51 38.6
Method of payment Self 48 36.4
Free/ fully subsidised 84 63.6
Table 2  Cause Of ESRD
Cause of ESRD No of subjects (%)
Unknown 53 (40.2)
Diabetic nephropathy 43 (32.6)
Chronic Glomerulonephritis 21 (15.9)
Obstructive Uropathy 7 (5.3)
Analgesic nephropathy 5 (3.8)
Polycystic kidney 3 (2.3)
Further analysis showed no 
sociodemographic factors difference between 
haemodialysis and CAPD patients except for the 
method of payment whereby more patients were 
receiving free treatment for both hemodialyses 
(55.56%) and CAPD (87.88%) (TABLE 3). 
However there were differences between the 2 
groups for Diabetis Mellitus, hypertension, 
albumin, cholesterol and urea level and also Kt/v 
value. Haemodialysis patients are more likely to 
be hypertensive but not diabetic or had 
cardiovascular disease compared to CAPD .
Haemodialysis patients also have a 
higher albumin and urea level but not for 
cholesterol and Kt/V value as compared to 
CAPD patients. 
During the 5 years period of observation 
(TABLE 4) 7.1% of haemodialysis and 15.2% of 
CAPD patients died, and the mortality incidence 
rate for CAPD subjects were higher (100.10 per 
100 persons years) as compared to haemodialysis 
subjects (3.26 per 100 persons years), but the 
difference of mortality incidence between the 
two treatments were not significant (RR 2.35, 
95% CI: 0.69-7.97). 
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Table 3  The Comparison Between Haemodialysis and CAPD Subjects According To 
Sociodemographic Factors, Smoking, Nutritional Parameter and Kt/V
Factors Characteristic HD n (%) CAPD
n (%)
p RR
(95% CI)
Sex Male 58 (73.4) 21 (26.6) 0.608 0.81 (0.36-1.83)
Female 41 (77.4) 12 (22.6) 1.0
Age of treatment Mean 50.67 48.33 0.332a
Ethnic Malay 61 (70.1) 26 (29.9) 0.072 1.0
Non- Malay 38 (84.4) 7 (15.6) 2.31 (0.92-5.851)
Marital status Married 81 (74.3) 27.3 (25.7) 0.691 1.0
Single 18 (78.3) 5 (21.7) 1.24 (0.42-3.66)
Educational level Primary school and less 45 (83.3) 9 (16.7) 0.066 2.22 (0.94-5.26)
Secondary school and 
upper
54 (69.2) 24 (30.8) 1.0
Income < RM1000 65 (80.2) 16 (19.8) 0.079 2.03 (0.91-4.51)
> RM1000 34 (66.7) 17 (33.3) 1.0
Method of payment Self 44 (91.7) 4 (8.3) 0.001 5.80 (1.90-17.74)
Free/ fully subsidised 55 (65.5) 29 (34.5) 1.0
Smoking Non-smoker 65 (78.3) 18 (21.7) 0.253 1.59 (0.72-3.55)
Smoker 34 (69.4) 15 (30.6) 1.0
diabetes mellitus Present 30 (61.2) 19 (38.8) 0.005 0.32 (0.14-0.72)
Absent 69 (83.1) 14 (16.9) 1.0
Hypertension Present 78 (71.6) 31 (28.4) 0.047 0.24 (0.05-1.08)
Absent 21 (91.3) 2 (8.7) 1.0
Cardiovascular 
disease (CVD)
Present 13 (54.2) 11 (45.8) 0.009 0.30 (0.12-0.77)
Absent 86 (79.6) 22 (20.4) 1.0
Body mass index 
(BMI) 
Mean 22.93 24.62 0.069a
Albumin (g/l) Mean 40.81 36.60 0.0005a
Cholesterol 
(mmol/l)
Mean 4.82 5.55 0.001a
Triglyceride 
(mmol/l)
Mean 2.13 2.43 0.370a
Kreatinin (umol/l) Mean 885.87 866.99 0.601a
Urea (mmol/l) Mean 19.92 16.05 0.0005a
Haemoglobin (g/dl) Mean 10.13 10.23 0.525a
Kt/V Mean 1.51 1.98 0.0005a
aMann-Whitney U test
Table 4  The Comparison Of Mortality According To The Type Of Dialysis
Status Alive
n (%)
Died
n (%)
Incidence per 100 
persons years
p RR ( 95% CI)
Haemodialysis 92 (92.9) 7 (7.1) 3.26 0.174a 2.35 (0.69 - 7.97)
CAPD 28 (84.8) 5 (15.2) 100.10 1.0
a χ2–test with Yates correction 
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Figure 1 Survival Curve According To The Treatment
Kaplan-Meier analysis showed that 
there were no difference of survival rate between 
the two treatments (log rank: p=0.093) although 
during the first 10 months of observation the 
CAPD subjects have better survivorship 
(FIGURE 1) as compared to haemodialysis 
subjects. Factors identified (TABLE 5) 
influencing the survival of haemodialysis 
subjects were diabetes mellitus (p=0.014), 
albumin level (p=0.0005), creatinine level 
(p=0.020) and haemoglobin level (p=0.002), 
whereas for CAPD subjects were age of initial 
treatment (p=0.039), diabetes mellitus (p=0.038), 
CVD (0.002) and Kt/V (p=0.0005) for CAPD 
subjects. 
Table 5 The Comparison Of Subjects By Sociodemographic Factors, Smoking, Nutritional Parameter 
And Kt/V For Each Treatment Group
Factors Characteristic Haemodialysis CAPD 
Mean 
(month)
P
(log rank)
Mean
(month)
P
(log rank)
Sex Male 56.53 0.295 36.63 0.966
Female 53.34 34.44
Age < 50 55.24 0.821 # 0.039
> 50 53.91 30.44
Ethnic Malay 55.38 0.655 35.36 0.291
Non- Malay 53.53 25.41
Marital status Married 54.27 0.198 33.76 0.329
Single # #
Educational level Primary school and less 52.01 0.933 # 0.147
Secondary school and 
upper
55.07 32.51
Income < RM 1000 55.02 0.748 39.20 0.165
> RM 1000 54.58 30.97
p > 0.05
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Method of 
payment
Self 53.53 0.882 # 0.316
Free/ subsidised 55.43 33.71
Smoking Non-smoker 54.87 0.776 32.57 0.346
Smoker 54.86 38.85
Diabetes mellitus Present 41.81 0.014 30.13 0.038
Absent 57.82 #
Hypertension Present 55.13 0.653 34.62 0.605
Absent 51.48 #
Cardiovascular 
disease (CVD)
Present 46.10 0.326 17.86 0.002
Absent 55.84 39.33
Body mass index 
(BMI)
< 23 55.10 0.485 # 0.412
> 23 55.06 34.37
Albumin (g/l) < 35 46.48 0.0005 33.58 0.121
> 35 # #
Cholesterol 
(mmol/l)
< 5.2 56.03 0.474 31.86 0.302
> 5.2 52.07 36.87
Triglyceride 
(mmol/l)
< 1.7 52.80 0.136 23.23 0.081
> 1.7 58.22 37.65
Creatininea 
(umol/l)
< 858.4 49.58 0.020 31.02 0.055
> 858.4 58.44 #
Ureaa (mmol/l) < 18.85 53.95 0.383 34.82 0.763
> 18.85 55.11 27.47
Haemoglobina
(g/dl)
< 10 49.05 0.002 34.85 0.861
> 10 # 28.55
Kt/V < 1.2 52.27 0.289 8.68 0.0005
> 1.2 55.91 35.85
# The expected survival was not calculated as all subjects were censored. 
a Categorised at median 
Table 6 shows the result of Cox 
Proportional Hazard Regression. Factors 
identified to reduce the survival of haemodialysis 
patients were low albumin (HR 0.669, 95% CI: 
0.513 - 0.873) and haemoglobin level (HR 0.403, 
95% CI: 0.225 - 0.720), but there was no factor 
found influencing the survival of CAPD patient.
Table 6 Hazard Ratio Of Factors Studied For Haemodialysis Subjects
Factor B SE Wald dk p Hazard Ratio 
(Exp(B)
95.0% CI (HR)
Albumin -0.402 0.136 8.788 1 0.003 0.669 0.513 – 0.873
Hb -0.910 0.297 9.390 1 0.002 0.403 0.225 - 0.720
DISCUSSION 
Comparative analyses have been done 
for haemodialysis and CAPD treatment by using 
χ2–test and t-test where appropriate and also 
Mann-Whitney U test followed by Kaplan-Meier 
and Cox Proportional Hazard Regression. The 
total number of patients was 197, not much 
different compared to the local study with 217 
patients. Of the 132 subjects selected, more 
patients received haemodialysis treatment (99 
patients) compared to CAPD (33 patients), since 
CAPD is only available from the year 2000 at 
Hospital Tengku Ampuan Afzan20.
Majority of the cause of ESRD were 
unknown (40.2%). However, for the known 
cause diabetes mellitus was the main cause of the 
disease (32.58%). This doesn’t differ much from 
the study done earlier for the whole Malaysia 
between 2002 and 2003. Therefore effort must be 
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intensified towards prevention and control of 
diabetes mellitus3. 
Majority of the subjects were Malay 
(65.9%). This might be due the fact that other 
ethnicities tend to receive treatment from the 
private centre which were not included in this 
study. There were more male patients (59.8%) in 
this study even after the subjects were divided 
according to type of dialysis treatment given 
(Haemodialysis: Male 58.6%, CAPD: Male 
63.6%). This may reflect the higher incidence 
rate and poor control of diabetes mellitus in male 
patients. Majority of CAPD patients (87.9%) 
received free treatment as compared to 
haemodialysis (55.6%) and the difference was 
statistically significant (p=0.001). But more 
haemodialysis patients have income of less than 
RM1000 per month (65.7%) as compared to 
CAPD (48.5%) although it was not statistically 
significant (p=0.079). This could be due to the 
majority of CAPD patients were government 
staff, or dependents of government staff.
The overall mortality rate for this study 
was 9.1%, less than the rate for Malaysia (10%) 
for the period of 1980 to 2003. May be it reflect 
the better services given by the government 
facilities in the state of Pahang. The mortality 
rate for CAPD was 15.2%, which was more than 
of haemodialysis patients (7.1%). This is 
consistent with the findings of a similar study6. 
The mortality incidence rate also higher for 
CAPD patients (100.10 per 100 person years) as 
compared to haemodialysis (3.26 per 100 person 
years). However the difference was not 
statistically significant (χ2, p=0.174). 
Kaplan-Meier analyses show a higher 
survival mean for haemodialysis (55 months) 
when compared to CAPD subjects (35 months). 
This occurs due to a higher mortality rate among 
CAPD patients, most likely due to presence of 
more elderly patients in the CAPD group. 
However there was no significant difference of 
survival rate between the two groups (log rank: 
p=0.093), although  a report showed that CAPD 
patients have 74% higher mortality compared to 
haemodialysis20. As we can see from FIGURE 1, 
the survival rate changes after 10 months of 
treatment. The haemodialysis group have better 
survival rate after 10 month of treatment but 
CAPD patients have better survival rate earlier 
on. 
The study also found that the presence 
of diabetes mellitus (p=0.014), albumin less than 
35g/l (p=0.0005), creatinine of more than 
858.4umol/l (p=0.020) and haemoglobin level 
less than 10g/dl (p=0.002) will influence the 
survival of haemodialysed patient. Whereas for 
CAPD patients, their survival was influenced by 
age at onset of treatment (p=0.039), the presence 
of diabetes mellitus (p=0.038), CVD (p=0.002) 
and the value of Kt/V less than 1.2 (p=0.0005). 
Significant factors from the Kaplan-
Meier analysis were included into the Cox 
Proportional Hazard Regression. For CAPD 
patients, none of the factors were found to be 
significant in the analysis. However for 
haemodialysis, the significant factors were 
albumin (p=0.003) and haemoglobin level 
(p=0.002).
Haemodialysis patients with higher 
albumin level (>35 g/l) have less mortality risk 
as compared to low albumin level (RR 0.669, 
95% CI: 0.513-0.873). This finding is similar 
with other studies3, 10 & 21.The problem of 
malnutrition is common in ESRD patients who 
receive haemodialysis treatment and the 
prevalence of this problem can affect up to 40% 
of the patients22,23. Several factors can cause 
malnutrition such as nutrient loss into the 
dialysate, nausea and loss of appetite, uraemia 
and also chronic blood loss. Albumin level is one 
of malnutrition parameter and is an indicator for 
the protein storage in the body22. It can change 
due to process of catabolism such as infection 
that is common in these patients. 
ESRD patients who receive 
haemodialysis treatment and have low 
haemoglobin level will have higher mortality risk 
(RR 0.403, 95% CI: 0.225-0.720), similar to 
other studies3,24. Anaemia is common among 
ESRD patients and due to the complication of 
uraemia25. The relationship of anaemia and risk 
of mortality could be due to malnutrition and 
systemic inflammation that are common in these 
patients24. These factors may lead to 
cardiovascular failure leading to high mortality. 
Limitation of the study
The main problem in conducting a study 
using secondary data is to obtain complete and 
reliable data whereby missing data is common.
In this study, 33.5% of total numbers of 
registered subjects were not included due to 
incompleteness of data, the subject received 
different kind of dialysis modality previously or 
underwent a renal transplant before. ‘Intention 
to-treat’ analyses may be useful to overcome this 
problem but the small number of subject may 
hinder its usefulness. 
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The other problem was that only a small 
number of the subjects had achieved the primary 
end point (died: 7 for haemodialysis and 5 for 
CAPD), therefore it was difficult to calculate the 
median of the survival time or the time 
corresponding to a survival portion of 0.5 in the 
survival curve. This also contributes to the 
situation where all subjects were censored or no 
primary end point was observed for certain 
factors being studied. The problem may be 
overcome by lengthening the observation to 8 or 
10 years. In addition the CAPD programme was 
only started at the year of 2000, thus the number 
of subjects that could be enrolled were limited. 
CONCLUSION
Despite the limitations, 2 factors were 
identified as potential predictor for the survival 
of haemodialysis patients. A higher albumin and 
haemoglobin level will improve the survival by 
seven and four time respectively. 
Albumin level is one of the nutritional 
status indicators and it should be maintained at a 
higher or adequate level to achieve better 
survival in haemodialysis patients. Every 
patient’s nutritional status should be assessed 
continuously. Any factors affecting the patient’s 
diet has to be looked at and the problems should 
be corrected. Appropriate diet counselling will 
ensure that they will have ample knowledge and 
understanding the important of good diet practice.
Anaemia is common in ESRD patients. 
Based on this study, a higher haemoglobin level 
will lead to better survival of haemodialysis 
patients. Currently not all patients are treated 
with erythropoietin to increase their haemoglobin 
level. Therefore this should become a standard 
treatment all haemodialysis patients in future, 
hopefully at no or little cost to them. 
The most important measure to 
overcome this problem is prevention of the 
disease (ESRD) itself. As diabetes mellitus had 
been identified as the major cause of this disease, 
the prevention, early detection and control 
program of diabetes mellitus should be 
strengthened continuously. All known diabetic 
patients should be treated adequately to delay the 
progression to renal disease. To ensure a good 
surveillance of these patients, perhaps a 
notification system for diabetes mellitus should 
be initiated.
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